Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
1. Azd-9291
2. Azd-9291 Mesylate
3. Azd9291
4. Azd9291 Mesylate
5. Mereletinib
6. Mereletinib Mesilate
7. Mereletinib Mesylate
8. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide
9. N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-2-propenamide Methanesulfonate (1:1)
10. Osimertinib
11. Osimertinib Mesilate
12. Tagrisso
1. 1421373-66-1
2. Azd-9291 Mesylate
3. Azd9291 Mesylate
4. Azd-9291 (mesylate)
5. Mereletinib Mesylate
6. Tagrisso
7. Osimertinib Mesilate
8. Mereletinib Mesilate
9. Osimertinib Mesylate [usan]
10. Rdl94r2a16
11. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(1-methylindol-3-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide;methanesulfonic Acid
12. N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide Methanesulfonate
13. Osimertinib Mesilate (jan)
14. Osimertinib Mesylate (usan)
15. 2-propenamide, N-(2-((2-(dimethylamino)ethyl)methylamino)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl)amino)phenyl)-, Methanesulfonate (1:1)
16. Osimertinib Mesilate [jan]
17. 2-propenamide, N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-, Compd. With Methanesulfonate (1:2)
18. Unii-rdl94r2a16
19. Tagrisso (tn)
20. Osimertinib Monomesylate
21. Azd 9291 Mesylate
22. Osimertinib Methanesulfonate
23. Amy226
24. Chembl3545063
25. Schembl14661152
26. Chebi:90948
27. Osimertinib Mesylate [mi]
28. Dtxsid101027822
29. Bcp09934
30. Ex-a1577
31. Hy-15772a
32. Mfcd28137994
33. Osimertinib Mesilate [who-dd]
34. Akos026673944
35. Ds-9913
36. Sb22953
37. Ac-29022
38. Da-35303
39. Osimertinib Mesylate [orange Book]
40. Azd-9291 Mesylate (osimertinibmereletinib)
41. Ft-0699962
42. S5078
43. D10766
44. Q27162942
45. Azd9291 Ms Salt, Osimertinib Ms Salt; Mereletinib Ms Salt
46. N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide Methanesulfonate
47. N-[2-[[2-(dimethylamino)ethyl]methylamino]-4-methoxy-5-[[4-(1-methyl-1h-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-2-propenamide Methanesulfonate
1. Osimertinib
Molecular Weight | 595.7 g/mol |
---|---|
Molecular Formula | C29H37N7O5S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 10 |
Exact Mass | 595.25768848 g/mol |
Monoisotopic Mass | 595.25768848 g/mol |
Topological Polar Surface Area | 150 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 845 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
TAGRISSO as monotherapy is indicated for:
-the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations
- the first-line treatment of adult patients NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
TAGRISSO as monotherapy is indicated for:
- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.
Antineoplastic Agents
Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
L01XE
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-05-06
Pay. Date : 2019-03-14
DMF Number : 32143
Submission : 2017-12-29
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0068
Start Marketing Date : 2017-12-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2024-12-19
Registration Number : No. 173-37-ND(1)
Manufacturer Name : MSN Laboratories Private Limited
Manufacturer Address : (Unit-ll) Sy. No. 50, 53, 53/A, 54 & 54/A, Kardanur (Village), Patancheru (Mandal), Sangareddy District, Telangana, Pincode: 502 300, India.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35581
Submission : 2021-02-04
Status : Active
Type : II
Registrant Name : Lihu Healthcare Co., Ltd.
Registration Date : 2024-03-18
Registration Number : Thu21-24-ND(1)
Manufacturer Name : Hetero Labs Limited(Unit-1)
Manufacturer Address : Survey No.10, IDA, Gaddapotharam Village, Jinnaram Mandal, SangaReddy District.-502319, Telangana, India
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-02-26
Pay. Date : 2018-12-12
DMF Number : 33409
Submission : 2018-12-31
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-02
Written Confirmation Number : WC-0082
Address of the Firm :
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-05-22
Registration Number : 434-56-ND
Manufacturer Name : Alembic Pharmaceuticals Limited
Manufacturer Address : API Division Karakhadi, Plot No. 842-843 Tal-Padra, City : Karakhadi-391 450, Dist : Vadodara, Gujarat State, India
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36546
Submission : 2021-12-24
Status : Active
Type : II
NDC Package Code : 54245-1451
Start Marketing Date : 2022-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Complete
Rev. Date : 2019-02-26
Pay. Date : 2018-12-12
DMF Number : 33409
Submission : 2018-12-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35581
Submission : 2021-02-04
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-05-06
Pay. Date : 2019-03-14
DMF Number : 32143
Submission : 2017-12-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36546
Submission : 2021-12-24
Status : Active
Type : II
Date of Issue : 2022-06-17
Valid Till : 2025-07-02
Written Confirmation Number : WC-0082
Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...
Date of Issue : 2021-10-05
Valid Till : 2022-07-02
Written Confirmation Number : WC-0082A11
Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm : MIs. MSN Laboratories Private Limited, Unit-II, sv. No, 50, Kardanur (Village), ...
Date of Issue : 2019-10-07
Valid Till : 2022-06-12
Written Confirmation Number : WC-0372
Address of the Firm : S. No. 73/1A, 74/7B, 78/1B, 79/1, 2B 3 4B 5 6A, 6B, 7, 80/1,2 3,4, 84/1, 2, 3A, ...
NDC Package Code : 54864-844
Start Marketing Date : 2015-11-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49187-0835
Start Marketing Date : 2015-11-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54893-0068
Start Marketing Date : 2017-12-29
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 65129-1451
Start Marketing Date : 2022-06-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 54245-1451
Start Marketing Date : 2022-06-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & F...
Faran Shimi: Leading producer of high-quality APIs & alkaloid opiates, serving major pharmaceutical companies across the Middle East.
About the Company : Faran Shimi Pharmaceutical Company, established in 2001 and affiliated with Golrang Pharmaceutical Investment Co, manufactures high-quality Active Pharmaceutical Ingredients (APIs)...
Aarti Pharmalabs is a partner of choice for APIs & Intermediates and the largest Indian manufacturer of Xanthine Derivatives.
About the Company : Aarti Pharmalab, earlier the pharma division of Aarti Industries, is a leading Indian manufacturer of APIs. It has dedicated facilities to manufacture HPAPIs, corticosteroids, cyto...
About the Company : Established in May 2012, Shandong Loncom Pharmaceutical operates as a fully owned subsidiary of Shandong Bestcomm Pharmaceutical Co., Ltd. Situated in the Qihe Economic Development...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long-standing tradition of advancing health through innovation and dedication. Today, we proudly build upon this legacy, drivi...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Bulat Pharmaceutical is a fast growing pharmaceutical company, founded in the year 2017, Bulat Pharmaceutical is engaged in the manufacturing and sales of high quality APIs and Int...
About the Company : Haoyuan Chemexpress Co., Ltd., located in Shanghai Zhangjiang Biomedical Base, is a high-tech company specializing in customized chemical synthesis and R&D of pharmaceutical interm...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Orpathys
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 01, 2025
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
HUTCHMED NDA Acceptance in China for ORPATHYS® & TAGRISSO® Lung Cancer
Details : Orpathys is an MET tyrosine kinase inhibitor. Tagrisso is a third-generation, irreversible EGFR TKI. These are being evaluated in combination with EGFR mutation-positive non-small cell lung cancer.
Product Name : Orpathys
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 01, 2025
Details:
Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.
Lead Product(s): Savolitinib,Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2024
Lead Product(s) : Savolitinib,Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
HUTCHMED Announces Breakthrough Therapy Designation in China for ORPATHYS® and TAGRISSO®
Details : Orpathys (savolitinib) is an oral, potent and highly selective MET tyrosine kinase inhibitor. It is investigated in combination with osimertinib for EGFR-mutated NSCLC.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 11, 2024
Details:
Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.
Lead Product(s): Osimertinib Mesylate,Savolitinib
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2024
Lead Product(s) : Osimertinib Mesylate,Savolitinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TAGRISSO® and ORPATHYS® Show High Response in MET-Positive Lung Cancer in SAVANNAH Study
Details : Tagrisso (osimertinib) is being evaluated in the mid-stage clinical trial studies in combination with Orpathys (savolitinib) for EFGR-mutated non-small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
October 16, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2024
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TAGRISSO® Approved For Unresectable Stage III EGFR-Mutated Lung Cancer
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is indicated for treatment of patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
September 26, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2024
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EU Approves AstraZeneca’s Tagrisso with Chemotherapy for EGFR-Mutated Lung Cancer
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2024
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tagrisso Granted Priority Review for Unresectable Stage III Lung Cancer
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2024
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
TAGRISSO® Reduces Disease Progression Risk by 84% in Stage III EGFR-Mutated Lung Cancer
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
June 02, 2024
Details:
Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2024
Lead Product(s) : Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tagrisso Shows Favorable Survival Trend with Chemotherapy in EGFR-Mutated Lung Cancer
Details : Tagrisso (osimertinib mesylate) is a third-generation, irreversible EGFR-TKI, small molecule drug candidate which is being evaluated for the treatment of EGFR-mutated advanced lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
March 21, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Lead Product(s): Osimertinib Mesylate
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Lead Product(s) : Osimertinib Mesylate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tagrisso Shows Efficacy for Patients with Unresectable EGFR-Mutated Lung Cancer Trial
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI, which is being evaluated for patients with unresectable, Stage III EGFR-mutated non small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
February 19, 2024
Details:
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.
Lead Product(s): Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area: Oncology Brand Name: Tagrisso
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2024
Lead Product(s) : Osimertinib Mesylate,Pemetrexed,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tagrisso with Chemotherapy Approved in the US for EGFR-Mutated Advanced Lung Cancer
Details : Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI which is approved in combination with chemotherapy for the treatment of EGFR-mutated advanced non-small cell lung cancer.
Product Name : Tagrisso
Product Type : Small molecule
Upfront Cash : Not Applicable
February 16, 2024
RLD : Yes
TE Code :
Brand Name : TAGRISSO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 40MG BASE
Approval Date : 2015-11-13
Application Number : 208065
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
Brand Name : TAGRISSO
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 80MG BASE
Approval Date : 2015-11-13
Application Number : 208065
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : OSIMERTINIB MESYLATE
Dosage Form : TABLET;ORAL
Dosage Strength : 40MG
Approval Date :
Application Number : 214263
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : OSIMERTINIB MESYLATE
Dosage Form : TABLET;ORAL
Dosage Strength : 80MG
Approval Date :
Application Number : 214263
RX/OTC/DISCN :
RLD :
TE Code :
Regulatory Info :
Registration Country : Sweden
Brand Name : TAGRISSO
Dosage Form : FILM COATED PILL
Dosage Strength : 80 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : TAGRISSO
Dosage Form : FILM COATED PILL
Dosage Strength : 40 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Tagrisso
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 40 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Tagrisso
Dosage Form : Antic-calc Tablet, Film Coated
Dosage Strength : 80 mg
Packaging : Blister
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tagrisso
Dosage Form : Tabl
Dosage Strength : 40mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Tagrisso
Dosage Form : Tabl
Dosage Strength : 80mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Canada
OSIMERTINIB (OSIMERTINIB MESYLATE)
Brand Name : TAGRISSO
Dosage Form : TABLET
Dosage Strength : 80MG
Packaging : 30
Approval Date :
Application Number : 2456222
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Canada
OSIMERTINIB (OSIMERTINIB MESYLATE)
Brand Name : TAGRISSO
Dosage Form : TABLET
Dosage Strength : 40MG
Packaging : 30
Approval Date :
Application Number : 2456214
Regulatory Info :
Registration Country : Canada
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Australia
Brand Name : Tagrisso
Dosage Form :
Dosage Strength :
Packaging : 30
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info :
Registration Country : Hungary
Brand Name :
Dosage Form : Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Hungary
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 40MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Hungary
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Regulatory Info :
Registration Country : Hungary
Brand Name :
Dosage Form : Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Hungary
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 80MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Hungary
Regulatory Info :
Registration Country : Iran
Brand Name : Mertisso
Dosage Form : Film Coated Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 40MG
Brand Name : Mertisso
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Iran
Brand Name : Mertisso
Dosage Form : Film Coated Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Iran
Packaging :
Regulatory Info :
Dosage : Film Coated Tablet
Dosage Strength : 80MG
Brand Name : Mertisso
Approval Date :
Application Number :
Registration Country : Iran
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Tablet
Dosage Strength : 40MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 40MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Regulatory Info :
Registration Country : Turkey
Brand Name :
Dosage Form : Tablet
Dosage Strength : 80MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Turkey
Packaging :
Regulatory Info :
Dosage : Tablet
Dosage Strength : 80MG
Brand Name :
Approval Date :
Application Number :
Registration Country : Turkey
Global Sales Information
Market Place
Reply
29 Sep 2022
Reply
14 Jan 2022
Reply
04 Dec 2021
Reply
18 Mar 2021
Reply
19 Mar 2020
Reply
15 Sep 2018
Patents & EXCLUSIVITIES
Patent Expiration Date : 2035-01-02
US Patent Number : 10183020
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-3823
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-02
Patent Expiration Date : 2032-08-08
US Patent Number : 8946235
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-1777
Delist Requested :
Patent Use Description : TREATMENT OF PATIENTS ...
Patent Expiration Date : 2032-08-08
Patent Expiration Date : 2032-08-08
US Patent Number : 8946235
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-4010
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-08-08
Patent Expiration Date : 2032-07-25
US Patent Number : 11524951
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-25
Patent Expiration Date : 2032-07-25
US Patent Number : 9732058
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-2289
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-25
Patent Expiration Date : 2032-07-25
US Patent Number : 9732058
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-4010
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-25
Patent Expiration Date : 2035-01-02
US Patent Number : 10183020
Drug Substance Claim :
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-3823
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2035-01-02
Patent Expiration Date : 2032-08-08
US Patent Number : 8946235
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-2289
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-08-08
Patent Expiration Date : 2032-07-25
US Patent Number : 11524951
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code :
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-25
Patent Expiration Date : 2032-07-25
US Patent Number : 9732058
Drug Substance Claim : Y
Drug Product Claim : Y
Application Number : 208065
Patent Use Code : U-4010
Delist Requested :
Patent Use Description :
Patent Expiration Date : 2032-07-25
Exclusivity Code : ODE-176
Exclusivity Expiration Date : 2025-04-18
Application Number : 208065
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-337
Exclusivity Expiration Date : 2027-12-18
Application Number : 208065
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-941
Exclusivity Expiration Date : 2027-02-16
Application Number : 208065
Product Number : 1
Exclusivity Details :
Exclusivity Code : I-952
Exclusivity Expiration Date : 2027-09-25
Application Number : 208065
Product Number : 1
Exclusivity Details :
Exclusivity Code : ODE-176
Exclusivity Expiration Date : 2025-04-18
Application Number : 208065
Product Number : 2
Exclusivity Details :
Exclusivity Code : ODE-337
Exclusivity Expiration Date : 2027-12-18
Application Number : 208065
Product Number : 2
Exclusivity Details :
Exclusivity Code : I-941
Exclusivity Expiration Date : 2027-02-16
Application Number : 208065
Product Number : 2
Exclusivity Details :
Exclusivity Code : I-952
Exclusivity Expiration Date : 2027-09-25
Application Number : 208065
Product Number : 2
Exclusivity Details :
Patent Expiration Date : 2032-07-25
Date Granted : 2015-06-16
Brand Name : TAGRISSO
Patent Number : 2843109
Filing Date : 2012-07-25
Strength per Unit : 40mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2032-07-25
Date Granted : 2015-06-16
Patent Expiration Date : 2032-07-25
Date Granted : 2015-06-16
Brand Name : TAGRISSO
Patent Number : 2843109
Filing Date : 2012-07-25
Strength per Unit : 80mg
Dosage Form : TABLET
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2032-07-25
Date Granted : 2015-06-16
ABOUT THIS PAGE
71
PharmaCompass offers a list of Osimertinib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Osimertinib Mesylate manufacturer or Osimertinib Mesylate supplier.
PharmaCompass also assists you with knowing the Osimertinib Mesylate API Price utilized in the formulation of products. Osimertinib Mesylate API Price is not always fixed or binding as the Osimertinib Mesylate Price is obtained through a variety of data sources. The Osimertinib Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Osimertinib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Osimertinib Mesylate, including repackagers and relabelers. The FDA regulates Osimertinib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Osimertinib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Osimertinib Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Osimertinib Mesylate supplier is an individual or a company that provides Osimertinib Mesylate active pharmaceutical ingredient (API) or Osimertinib Mesylate finished formulations upon request. The Osimertinib Mesylate suppliers may include Osimertinib Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Osimertinib Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Osimertinib Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Osimertinib Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Osimertinib Mesylate DMFs exist exist since differing nations have different regulations, such as Osimertinib Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Osimertinib Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Osimertinib Mesylate USDMF includes data on Osimertinib Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Osimertinib Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Osimertinib Mesylate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Osimertinib Mesylate Drug Master File in Korea (Osimertinib Mesylate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Osimertinib Mesylate. The MFDS reviews the Osimertinib Mesylate KDMF as part of the drug registration process and uses the information provided in the Osimertinib Mesylate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Osimertinib Mesylate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Osimertinib Mesylate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Osimertinib Mesylate suppliers with KDMF on PharmaCompass.
A Osimertinib Mesylate written confirmation (Osimertinib Mesylate WC) is an official document issued by a regulatory agency to a Osimertinib Mesylate manufacturer, verifying that the manufacturing facility of a Osimertinib Mesylate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Osimertinib Mesylate APIs or Osimertinib Mesylate finished pharmaceutical products to another nation, regulatory agencies frequently require a Osimertinib Mesylate WC (written confirmation) as part of the regulatory process.
click here to find a list of Osimertinib Mesylate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Osimertinib Mesylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Osimertinib Mesylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Osimertinib Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Osimertinib Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Osimertinib Mesylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Osimertinib Mesylate suppliers with NDC on PharmaCompass.
Osimertinib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Osimertinib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Osimertinib Mesylate GMP manufacturer or Osimertinib Mesylate GMP API supplier for your needs.
A Osimertinib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Osimertinib Mesylate's compliance with Osimertinib Mesylate specifications and serves as a tool for batch-level quality control.
Osimertinib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Osimertinib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Osimertinib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Osimertinib Mesylate EP), Osimertinib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Osimertinib Mesylate USP).